Suggested remit: To appraise the clinical and cost effectiveness of ruxolitinib within its marketing authorisation for treating non-segmental vitiligo in people 12 years and over.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 3998

Provisional Schedule

Committee meeting: 2 06 June 2024
Expected publication 31 July 2024

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Stakeholders

Companies sponsors Incyte (ruxolitinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Gene People
  Vitiligo Society
  Vitiligo Support UK
Professional groups British Association of Dermatologists
  British Dermatological Nursing Group
  Royal College of Physicians
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
09 April 2024 In February 2024, we informed you that the company, Incyte Corporation, was going to provide additional evidence in response to the draft guidance consultation. To allow time for the additional evidence to be submitted by the company and to be critiqued by the External Academic Group, we postponed the second committee meeting discussion. I can confirm that the second committee meeting discussion has now been scheduled for 6 June 2024. Details to register to observe the second committee meeting in June will be available on the NICE Meetings in public webpage from mid May 2024.
31 January 2024 - 21 February 2024 Draft guidance
07 February 2024 We issued draft guidance for consultation on 24 January 2024 and the company, Incyte Corporation, has asked to provide additional evidence to address the committee’s requests as part of their response to the consultation. To allow time for the additional evidence to be submitted by the company and to be critiqued by the External Academic Group, this will no longer be discussed at the committee meeting on 6 March 2024. The second committee meeting discussion will be rearranged, and we will update all stakeholders with the new date in due course.
11 January 2024 Committee meeting
08 June 2023 Invitation to participate
11 May 2023 (14:00) Scoping workshop
16 March 2023 - 17 April 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3998
17 June 2022 Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-April 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
24 November 2021 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual